Immatics (IMTX) Income from Continuing Operations (2019 - 2025)
Immatics (IMTX) reported Income from Continuing Operations of 41242061.73 for Q4 2025, down 184.29% on a YoY basis from 48927777.59 in Q4 2024, and up 30.55% sequentially from 59386829.59 in Q3 2025.
Immatics (IMTX) Income from Continuing Operations (2019 - 2025) Analysis & Trends
Immatics (IMTX) has 7 years of Income from Continuing Operations data on file, last reported at 41242061.73 in Q4 2025.
- For the quarter ending Q4 2025, Income from Continuing Operations fell 184.29% year-over-year to 41242061.73; the trailing twelve-month figure through Dec 2025 stood at 226540175.34 (down 875.72% YoY), and the FY2025 full-year result was 226442407.73, down 861.51% from the prior year.
- Income from Continuing Operations improved to 41242061.73 in Q4 2025, from 59386829.59 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 96141693.63 in Q1 2022 to a low of 81897283.43 in Q2 2025.
- A 5-year average of 17355436.62 and a median of 23996855.1 in 2023 frame the typical range for Income from Continuing Operations.
- Across the five-year window, Income from Continuing Operations jumped 449.38% in 2022 and slumped 9127.64% in 2025, its largest moves.
- Tracing IMTX's Income from Continuing Operations over 5 years: stood at 19203840.36 in 2021, then surged by 111.78% to 2261888.41 in 2022, then plunged by 1343.81% to 28133676.74 in 2023, then jumped by 273.91% to 48927777.59 in 2024, then sank by 184.29% to 41242061.73 in 2025.
- Business Quant data shows IMTX's Income from Continuing Operations at 41242061.73 in Q4 2025, 59386829.59 in Q3 2025, and 81897283.43 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -14.46 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 227.36 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 498.00 Mn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -453.82 Mn |
| 10 | Immatics | 1.11 Bn | 1.11 Bn | - | -41.24 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -41.24 Mn |
| Sep 30, 2025 | -59.39 Mn |
| Jun 30, 2025 | -81.90 Mn |
| Mar 31, 2025 | -44.01 Mn |
| Dec 31, 2024 | 48.93 Mn |
| Sep 30, 2024 | 657,833.48 |
| Jun 30, 2024 | -19.07 Mn |
| Mar 31, 2024 | -1.31 Mn |
| Dec 31, 2023 | -28.13 Mn |
| Sep 30, 2023 | -28.84 Mn |
| Jun 30, 2023 | -26.80 Mn |
| Mar 31, 2023 | -21.20 Mn |
| Dec 31, 2022 | 2.26 Mn |
| Sep 30, 2022 | -19.98 Mn |
| Jun 30, 2022 | -12.47 Mn |
| Mar 31, 2022 | 96.14 Mn |
| Dec 31, 2021 | -19.20 Mn |
| Sep 30, 2021 | -32.08 Mn |
| Jun 30, 2021 | -31.95 Mn |
| Mar 31, 2021 | -27.52 Mn |